Lyra Therapeutics Files Proxy Materials
Ticker: LYRA · Form: DEFA14A · Filed: May 9, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | DEFA14A |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
TL;DR
Lyra Therapeutics filed proxy docs, likely for shareholder votes. Standard procedure.
AI Summary
Lyra Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on May 9, 2025. This filing relates to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The company is incorporated in Delaware and headquartered in Watertown, MA.
Why It Matters
This filing indicates that Lyra Therapeutics is engaging with its shareholders regarding corporate governance and voting matters, which is a standard but important part of public company operations.
Risk Assessment
Risk Level: low — This is a routine SEC filing (DEFA14A) for proxy materials, not indicating any specific financial distress or unusual corporate activity.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- 0001193125-25-116890 (filing_id) — Accession Number
- 20250509 (date) — Filing Date
- Watertown, MA (location) — Company Headquarters
- 480 ARSENAL WAY (address) — Company Business Address
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for a proxy statement.
Who is the filing company?
The filing company is Lyra Therapeutics, Inc.
When was this filing submitted?
The filing was submitted on May 9, 2025.
Where is Lyra Therapeutics, Inc. located?
The company's business and mailing address is 480 Arsenal Way, Watertown, MA 02472.
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used to provide definitive proxy materials to shareholders, typically in connection with a shareholder meeting where votes are cast on corporate matters.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 9, 2025 regarding Lyra Therapeutics, Inc. (LYRA).